Curcumin in Oncology

A comprehensive workbook by Abbey Mitchell for The Healing Cancer Study Support Group.

View contents menu

Contents - Curcumin in Oncology

Navigation of contents via blue hyperlinks does not work unless you are an editor working in Google Sheets

Ferroptosis-Dependence (Inducer)

References for Mechanisms of Action

Pharmacokinetics & Metabolism

Bioavailability (Oral %)

CYP Metabolism

Key Transporters

Protein Binding %

Plasma Half-Life

Clearance Route

Blood-Brain Barrier Penetration

References for Pharmacokinetics & Metabolism

Immune System Effects

Th1 vs Th2 Shift

Macrophage Polarization

NK Cell Effects

Dendritic Cell Effects

Overall Immune Impact

Safety & Interactions

Dose-Limiting Toxicity

QT Prolongation

Blood Thinning Effects

Major Drug-Drug Interactions

Food Interactions

Contraindications

Monitoring Requirements

Synergistic Combinations

CURCUMIN

Sharing this workbook: Please do not copy and paste sections and only share in full via these links:

Need to preview, save, and print it? You can open and preview before you download this PDF from the group's www.myhealingcommunity website media library: https://myhealingcommunity.com/wp-content/uploads/2026/02/Curcumin-in-Oncology-www.myhealingcommunity.com-Google-Sheets.pdf

Traditional Use: Ayurvedic medicine has used turmeric for millennia to treat inflammatory conditions, wounds, and digestive ailments. Modern research has validated many of these traditional uses while uncovering potent anticancer mechanisms.

Active Constituents: Curcuminoids (curcumin, *demethoxy*curcumin, *bisdemethoxy*curcumin)

Category: Polyphenol, Anti-inflammatory, Antioxidant, Supplement

Overview

Curcumin, the primary bioactive compound in turmeric (Curcuma longa), is one of the most extensively researched natural compounds in oncology. With more than 15,000 published studies, curcumin demonstrates multitarget anticancer effects across numerous cancer types. The C3 Complex® formulation used in cancer research and by several supplement brands provides a standardised blend of three curcuminoids, offering superior bioactivity compared to single-compound extracts.

Curcumin has been shown to modulate multiple hallmarks of cancer simultaneously—including proliferation, apoptosis, angiogenesis, metastasis, and inflammation—while exhibiting minimal toxicity. The liposomal C3 Complex® formulation addresses curcumin's primary limitation: poor bioavailability.

Traditional Ayurvedic medicine has used turmeric for millennia to treat inflammatory conditions, wounds, and digestive ailments. Modern research has validated many of these traditional uses while uncovering it's potent anticancer mechanisms.



Curcumin's Evidence Summary

Evidence Quality Rating: ★★★★☆ (4/5 - Strong Clinical Evidence)

Breakdown:

✓ Extensive preclinical data across dozens of cancer types

✓ Multiple Phase I and Phase II clinical trials

✓ Phase III trials emerging (ongoing)

✓ Meta-analyses support efficacy in colorectal cancer prevention
Limited Phase III data for active cancer treatment (most evidence is adjunctive/preventive)

Clinical Application Status:

Approved: Not FDA-approved as a cancer treatment (only a dietary supplement status)
Clinical use: Widely used as a complementary/adjunctive therapy
Evidence strength: Strong for prevention, moderate-to-strong for adjunctive support

Bottom Line for Cancer Patients:

Curcumin C3 Complex is among the most researched and promising natural compounds in integrative oncology. Given its robust safety profile, multi-targeted mechanisms, and growing clinical evidence, it warrants serious consideration as part of a comprehensive cancer strategy.

Key Advantages:

Exceptional safety (even at high doses)
Multi-pathway anticancer effects
Immune system support
May enhance conventional treatment efficacy
Anti-inflammatory benefits

Key Considerations:

Bioavailability is critical; —liposomal formulation is strongly preferred over the standard.
Best used as adjunctive therapy, not monotherapy
Coordinate with the oncology team, especially regarding chemotherapy combinations.
Consistent long-term use is likely needed for benefits.

If viewing a downloaded copy use the menu button (3 horizontal lines) to navigate the pages/sheets of this workbook and if using the online view only version use the tabs below to navigate the pages of the workbook.

Curcumin's Primary Anticancer Mechanisms:



1. NF-κB Inhibition (Master Regulator)
- Blocks IκB kinase (IKK), preventing NF-κB activation
- Reduces inflammatory signalling driving tumour progression
- Decreases expression of anti-apoptotic proteins (Bcl-2, Bcl-xL)

2. Multi-Kinase Inhibition
- EGFR, HER2, VEGFR (anti-angiogenic)
- PI3K/Akt/mTOR pathway suppression
- MAPK/ERK pathway inhibition
- JAK/STAT3 blockade

3. Apoptosis Induction
- Activates caspase-3, -8, and -9
- Increases Bax/Bcl-2 ratio
- Mitochondrial membrane disruption

4. Cell Cycle Arrest
- G1/S and G2/M cell-cycle arrest
- Modulates cyclins and CDKs

5. Anti-Metastatic Effects
- Inhibits MMP-2 and MMP-9 (matrix metalloproteinases)
- Reduces epithelial-mesenchymal transition (EMT)
- Suppresses CXCR4 chemokine signaling

6. Anti-Angiogenic
- Decreases VEGF expression

- Inhibits tumour blood vessel formation

Secondary Mechanisms:
Epigenetic modulation (HDAC and DNMT inhibition)
Cancer stem cell targeting
Autophagy induction (context-dependent)
Telomerase inhibition

References for Primary Anticancer Actions

Antioxidant curcumin induces oxidative stress to kill tumourtumor cells" by Hu et al., 2023–2024
https://pmc.ncbi.nlm.nih.gov/articles/PMC10773205/

Nrf2 Regulation by Curcumin: Molecular Aspects for Chemopreventive and Therapeutic Use" (Shahcheraghi et al.)
https://pmc.ncbi.nlm.nih.gov/articles/PMC8746993/

Curcumin induces ferroptosis in non-small-cell lung cancer cells via activating autophagy" by Tang et al.
https://pmc.ncbi.nlm.nih.gov/articles/PMC8046146/

Curcumin (diferuloylmethane) inhibits constitutive NF-κB and IκB kinase (IKK) in mantle cell lymphoma" (Aggarwal et al., 2005, Biochemical Pharmacology)
https://pubmed.ncbi.nlm.nih.gov/16023083/

Receptor Tyrosine Kinases and Their Signaling Pathways as Targets of Curcumin in Cancer Therapy" (Frontiers in Pharmacology, 2021)
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.772510/full

Mechanism insights of curcumin and its analogues in cancer" (Phytotherapy Research, 2023)
https://pubmed.ncbi.nlm.nih.gov/37649266/

Curcumin induces apoptosis through the mitochondria-mediated pathway in HT-29 colon cancer cells" (Wang et al., 2009)
https://pmc.ncbi.nlm.nih.gov/articles/PMC2644749/

Anti-cancer effects of curcumin: cycle of life and death" (Sa & Das, 2008, Cancer Letters)
https://pmc.ncbi.nlm.nih.gov/articles/PMC2572158/

Antimetastatic Effects of Curcumin in Oral and Gastrointestinal Cancers" (Frontiers in Pharmacology, 2021)
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.668567/fullhttps://www.spandidos-publications.com/10.3892/or.2016.4669

Curcumin inhibits tumor epithelial–mesenchymal transition and metastasis via NKD2–Wnt–CXCR4 signaling in colorectal cancer" (Zhang et al., 2016, Oncology Reports)

"Curcumin and Cancer" in Nutrients (2019; 11(10):2376)
https://pubmed.ncbi.nlm.nih.gov/31590362/

Exploring the Contribution of Curcumin to Cancer Therapy: A Systematic Review of Randomised Controlled Trials (2023)
https://pmc.ncbi.nlm.nih.gov/articles/PMC10144810/

Curcumin as a novel therapeutic candidate for cancer: can this natural compound revolutionise cancer treatment?
https://pmc.ncbi.nlm.nih.gov/articles/PMC11537944/

Curcumin's Mechanisms of Action

ROS-Dependence: CONTEXT-DEPENDENT (Dual Action)
Pro-oxidant at high doses: Generates ROS in cancer cells, leading to oxidative DNA damage and apoptosis
Antioxidant at low doses: Scavenges ROS and protects normal cells
Cancer cells with pre-existing oxidative stress are particularly vulnerable to curcumin's pro-oxidant effects

NRF2 Impact: ✓ ACTIVATOR (Potent)
Strongly activates NRF2 (Nuclear factor erythroid 2-related factor 2)
Upregulates Phase II detoxification enzymes: HO-1, NQO1, GST
Enhances cellular antioxidant capacity
Protective for normal cells; NRF2 may enhance chemoresistance in some contexts (use strategically)

Ferroptosis-Dependence: ✓ INDUCER (Emerging Evidence)
Recent studies show curcumin can trigger ferroptosis in resistant cancer cells
Depletes glutathione (GSH), increasing lipid peroxidation
Inhibits System Xc- (cystine/glutamate antiporter)



References for Mechanisms of Action

Antioxidant curcumin induces oxidative stress to kill tumourtumor cells" by Hu et al., 2023–2024
https://pmc.ncbi.nlm.nih.gov/articles/PMC10773205/

Nrf2 Regulation by Curcumin: Molecular Aspects for Chemopreventive and Therapeutic Use" (Shahcheraghi et al.)
https://pmc.ncbi.nlm.nih.gov/articles/PMC8746993/

Curcumin induces ferroptosis in non-small-cell lung cancer cells via activating autophagy" by Tang et al.
https://pmc.ncbi.nlm.nih.gov/articles/PMC8046146/

Curcumin (diferuloylmethane) inhibits constitutive NF-κB and IκB kinase (IKK) in mantle cell lymphoma" (Aggarwal et al., 2005, Biochemical Pharmacology)
https://pubmed.ncbi.nlm.nih.gov/16023083/

Receptor Tyrosine Kinases and Their Signaling Pathways as Targets of Curcumin in Cancer Therapy" (Frontiers in Pharmacology, 2021)
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.772510/full

Mechanism insights of curcumin and its analogues in cancer" (Phytotherapy Research, 2023)
https://pubmed.ncbi.nlm.nih.gov/37649266/

Curcumin induces apoptosis through the mitochondria-mediated pathway in HT-29 colon cancer cells" (Wang et al., 2009)
https://pmc.ncbi.nlm.nih.gov/articles/PMC2644749/

Anti-cancer effects of curcumin: cycle of life and death" (Sa & Das, 2008, Cancer Letters)
https://pmc.ncbi.nlm.nih.gov/articles/PMC2572158/

Antimetastatic Effects of Curcumin in Oral and Gastrointestinal Cancers" (Frontiers in Pharmacology, 2021)
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.668567/fullhttps://www.spandidos-publications.com/10.3892/or.2016.4669

Curcumin inhibits tumor epithelial–mesenchymal transition and metastasis via NKD2–Wnt–CXCR4 signaling in colorectal cancer" (Zhang et al., 2016, Oncology Reports)

"Curcumin and Cancer" in Nutrients (2019; 11(10):2376)
https://pubmed.ncbi.nlm.nih.gov/31590362/

Exploring the Contribution of Curcumin to Cancer Therapy: A Systematic Review of Randomised Controlled Trials (2023)
https://pmc.ncbi.nlm.nih.gov/articles/PMC10144810/

Curcumin as a novel therapeutic candidate for cancer: can this natural compound revolutionise cancer treatment?
https://pmc.ncbi.nlm.nih.gov/articles/PMC11537944/

Curcumin's Pharmacokinetics & Metabolism

Bioavailability (Oral %): <1% (Standard) or 10-30% (Liposomal formulation)
Major limitation: Poor water solubility, rapid metabolism, rapid elimination
Enhancement strategies: Liposomal delivery + piperine co-administration

CYP Metabolism:
Metabolized by: CYP3A4 (primary), CYP2C9, CYP1A2
Effect on CYPs: Mixed inhibitor and inducer
- *Inhibits:* CYP3A4, CYP2C9, CYP2D6 (modest)
- *May induce* CYP2B6 with chronic use
Clinical implication: Monitor when combining with CYP3A4 substrates (many anti-cancer agents)

Key Transporters:
Substrate of: P-glycoprotein (ABCB1) - contributes to poor bioavailability
Inhibits: P-gp, BCRP (ABCG2)
Effect: May increase levels of co-administered P-gp substrates

Protein Binding %: ~90% (primarily to albumin)

Plasma Half-Life (t½):
Free curcumin: 0.5-1.5 hours (very short)
Curcumin metabolites: 6-7 hours
Tissue retention: Much longer than plasma (days)

Clearance Route:
Primary: Hepatic metabolism → biliary excretion (fecal elimination ~60%)
Secondary: Renal excretion (~10% as metabolites)
Metabolites: Curcumin glucuronide, curcumin sulphate (less active), tetrahydrocurcumin (active)

Blood-Brain Barrier Penetration: POOR (standard), IMPROVED (liposomal)
Limited CNS penetration with standard formulations
Liposomal and nanoparticle forms show enhanced BBB crossing
Interest in glioblastoma and brain metastases





Summary of curcumin's oral bioavailability, ADME processes, metabolic modulation, transporter effects, and enhancement strategies (liposomal and piperine co-delivery)

References for Pharmacokinetics & Metabolism

Dietary Curcumin: Correlation between Bioavailability and Health Potential – Sciberras et al., 2019, Nutrients
https://pmc.ncbi.nlm.nih.gov/articles/PMC6770259/pmc.ncbi.nlm.nih

Bioavailable curcumin formulations: A review of pharmacokinetic studies in healthy volunteers – Cuomo et al., 2019, Pharmacological Research
https://pubmed.ncbi.nlm.nih.gov/30590123/ (via index)sciencedirect

Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers – Shoba et al., 1998, Planta Medica
https://pubmed.ncbi.nlm.nih.gov/9619120/thieme-connect+1

Inhibition of human recombinant cytochrome P450s by curcumin and its decomposition products – Volak et al., 2007, Toxicology in Vitro
https://pubmed.ncbi.nlm.nih.gov/17433521/pubmed.ncbi.nlm.nih

Impact of curcumin-induced changes in P-glycoprotein and CYP3A expression on pharmacokinetics of celiprolol and midazolam in rats – Zhang et al., 2007, Drug Metabolism and Disposition
https://pubmed.ncbi.nlm.nih.gov/17050652/pubmed.ncbi.nlm.nih

Food constituent– and herb–drug interactions in oncology – Pilla Reddy et al., 2021, British Journal of Clinical Pharmacology
https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.14822bpspubs.onlinelibrary.wiley

Improving Curcumin Bioavailability: Current Strategies and Clinical Implications – Rutz et al., 2021, Pharmaceutics
https://pmc.ncbi.nlm.nih.gov/articles/PMC8540263/pmc.ncbi.nlm.nih

Curcumin Formulations for Better Bioavailability: What We Learned from Clinical Trials Thus Far? – Kulkarni et al., 2023, ACS Omega
https://pubs.acs.org/doi/10.1021/acsomega.2c07326pubs.acs

Recent developments in delivery, bioavailability, absorption and metabolism of curcumin – Nelson et al., 2014, Journal of Nutritional Biochemistry
https://pmc.ncbi.nlm.nih.gov/articles/PMC3918523/pmc.ncbi.nlm.nih

Mechanism insights of curcumin and its analogues in cancer" (Phytotherapy Research, 2023)
https://pubmed.ncbi.nlm.nih.gov/37649266/

Curcumin's Immune System Effects

Th1 vs Th2 Shift: → Th1 PROMOTION (Pro-inflammatory, anticancer)

Increases IFN-γ (Th1 cytokine)
Reduces IL-4, IL-5, IL-13 (Th2 cytokines)
Rebalances Th1/Th2 ratio in cancer-induced Th2 dominance
Clinical benefit: Enhances cell-mediated tumour immunity

Macrophage Polarization: → M1 SKEWING (Anti-tumor)

Promotes M1 macrophage differentiation (pro-inflammatory, tumoricidal)
Inhibits M2 macrophage polarisation (tumour-promoting)
Enhances macrophage phagocytosis of tumour cells
Reduces tumour-associated macrophage (TAM) immunosuppressive functions

NK Cell Effects: ✓ ENHANCEMENT

Increases NK cell cytotoxicity against tumour cells
Upregulates activating receptors (NKG2D)
Enhances perforin and granzyme B expression
Protects NK cells from tumour-induced suppression

Dendritic Cell Effects: ✓ MATURATION & ACTIVATION

Promotes DC maturation and antigen presentation
Increases expression of MHC-II, CD80, and CD86
Enhances DC migration to lymph nodes
Improves T-cell priming capacity

Overall Immune Impact: IMMUNOSTIMULATORY (beneficial for cancer)

Reduces myeloid-derived suppressor cells (MDSCs)
May enhance checkpoint inhibitor efficacy (early research)
Anti-inflammatory for chronic inflammation; pro-inflammatory for acute tumour immunity.



Safety & Interactions

Dose-Limiting Toxicity: Generally very well tolerated

Doses up to 12g/day have been used safely in clinical trials
Mild GI symptoms (nausea, diarrhea) at very high doses (>8g)
No serious adverse events in most studies
Excellent safety profile compared to conventional chemotherapy

QT Prolongation: NO (not reported)

No significant cardiac toxicity observed
Safe for patients with cardiac concerns

Blood Thinning Effects: ✓ YES (Mild antiplatelet activity)

Inhibits platelet aggregation
May potentiate anticoagulant effects
Caution: Stop 1-2 weeks before surgery
Monitor if combining with warfarin, aspirin, clopidogrel, NSAIDs

Major Drug-Drug Interactions:

CYP3A4 substrates: May increase levels (docetaxel, paclitaxel, irinotecan, vincristine)
P-gp substrates: May increase levels (doxorubicin, digoxin)
Anticoagulants: Additive blood-thinning effects
Diabetes medications: May enhance hypoglycemic effects (monitor glucose)
Iron supplements: Curcumin chelates iron; separate dosing by 2+ hours

Food Interactions:

Take with a fatty meal for enhanced absorption (lipophilic compound)
Black pepper (piperine) dramatically increases bioavailability
Avoid taking simultaneously with high-calcium foods (may form complexes)

Contraindications:

Active bleeding disorders
Bile duct obstruction (cholagogue effect)
Gallstones (may stimulate the gallbladder)
Pregnancy/breastfeeding (insufficient safety data)
Scheduled surgery within 2 weeks (bleeding risk)

Monitoring Requirements:

Routine labs are generally not needed
Monitor INR if on anticoagulants
Monitor blood glucose if diabetic
Assess for GI symptoms at higher doses

Synergistic Combinations:

With Chemotherapy:

Paclitaxel, docetaxel (breast, ovarian cancer)
Gemcitabine (pancreatic cancer)
5-FU (colorectal cancer)
Cisplatin, carboplatin (various cancers)
Mechanism: Sensitises resistant cells, reduces side effects

With Natural Compounds:

Piperine (black pepper): huge bioavailability increase - ESSENTIAL for standard curcumin
Quercetin: Additive anti-inflammatory and apoptotic effects
EGCG (green tea): Synergistic in breast and prostate cancer
Resveratrol: Enhanced antioxidant and anti-angiogenic effects
Boswellia (AKBA): Combined anti-inflammatory action
Vitamin D3: Enhanced immune modulation

Curcumin’s Additional Properties

Anti-Pathogen Overlap: ✓ BROAD-SPECTRUM

Antibacterial:

Effective against H. pylori (gastric cancer link)
Activity against MRSA, E. coli, and S. aureus
Disrupts bacterial biofilms

Antiviral:

Inhibits viral replication (influenza, HSV, HPV)
HPV inhibition relevant for cervical cancer prevention

Anti-Fungal:

✓ YES - Active against Candida species
Inhibits Aspergillus and other pathogenic fungi
Useful for immunocompromised cancer patients

Anti-Parasitic:

Activity against protozoa and helminths

Optimal Timing & Dosing:

Several trials in healthy volunteers compared standard curcumin powder with micellar, phospholipid, or nanoparticle formulations and showed that a few hundred milligrams of the enhanced product can achieve plasma levels comparable to or higher than those achieved with multi-gram doses of standard curcumin.

Standard Dosing:

General health/prevention: free oral standard curcumin 500-1000mg daily (divided doses with piperine)

Cancer Research Table (note dosing in some key findings):

Cancer Type	Study Type	Key Findings/Outcome	Study Title & Year	Reference
Colorectal Cancer	Phase II Clinical Trial	Curcumin 4g/day showed 40% reduction in aberrant crypt foci; well-tolerated	Curcumin and Quercetin in Familial Adenomatous Polyposis (2006)	Cruz-Correa et al., Clin Gastroenterol Hepatol
Colorectal Cancer	Phase IIa Trial	360mg curcumin + 20mg piperine improved patient outcomes; biomarker modulation confirmed	Phase IIa Clinical Trial of Curcumin in Advanced Colorectal Cancer (2011)	He et al., Anticancer Research
Pancreatic Cancer	Phase II Trial	8g curcumin daily; disease stabilisation in 2/21 patients; MTD not reached	Phase II Trial of Curcumin in Gemcitabine-Resistant Pancreatic Cancer (2008)	Dhillon et al., Clin Cancer Res
Breast Cancer	Preclinical/In vitro	Synergistic effect with paclitaxel; inhibits EGFR and HER2 signalling	Curcumin Sensitises Breast Cancer Cells to Chemotherapy (2015)	Hu et al., Molecular Cancer
Breast Cancer	Phase I Safety Study	Up to 8g daily is well-tolerated in breast cancer patients	Dose-Escalation Study of Curcumin in Breast Cancer (2010)	Bayet-Robert et al., Cancer Biol Ther
Prostate Cancer	Phase II Trial	Combination with soy isoflavones decreased PSA levels in 35% of patients	Curcumin and Isoflavone in Prostate Cancer (2012)	Ide et al., Nutrition and Cancer
Head & Neck Cancer	Clinical Trial	Curcumin mouthwash reduced oral mucositis severity during radiation	Curcumin for Radiation Mucositis (2013)	Rao et al., Integr Cancer Ther
Multiple Myeloma	Phase I/II Trial	Down-regulation of NF-κB; stabilisation in some patients at 4-8g/day	Clinical Trial of Curcumin in Multiple Myeloma (2009)	Golombick et al., Br J Haematol
Lung Cancer	Preclinical	Inhibits EGFR and downstream signalling; enhances cisplatin efficacy	Curcumin in Non-Small Cell Lung Cancer (2014)	Chen et al., PLoS One
Gastric Cancer	Meta-analysis	Significant reduction in gastric cancer risk with dietary curcumin	Curcumin and Gastric Cancer Risk (2016)	Zhang et al., Nutrients

Timing:

Free oral curcumin with meals (especially fatty foods) for absorption

Liposomal formulas 20 min before food with plenty of water

Take several doses no more than an hour apart (short half-life)

If combining with piperine: take together, not separately

Combining with luteolin, which inhibits the Nrf2 pathway in vivo, could enhance its cytotoxicit's cytoxic effects

Cycling:

In the 2.5 g liposomal range, a 5-day-on, 2-day-off approach could prevent tolerance

Dosing Consideration Notes

The IV route dosing seen in phase II cancer research bypasses the gut and first-pass liver metabolism; thus, 100% of the administered dose is initially bioavailable in the bloodstream, subject only to distribution and clearance.

In a typical 60 kg adult, a 300 mg/m² IV dose corresponds to approximately 500 mg of liposomal curcumin delivered via IV.

Standard oral or 'free' curcumin has <5% bioavailability; some liposomal formulations in animals reach around 30% oral bioavailability, roughly a 6-fold improvement over free curcumin, but this is still far below IV.

If we assume a conservative 20% oral liposomal bioavailability, then delivering about 500 mg systemically might require approximately 2.5 g of oral liposomal curcumin over a similar 6-hour window, but this is an educated estimate, not a clinically established conversion.

2.5 g of oral liposomal curcumin over a 6-hour window might look like:

12pm: 2 x 250mg capsules
1pm: 2 x 250mg capsules
2pm: 2 x 250mg capsules
3pm: 2 x 250mg capsules
4pm: 2 x 250mg capsules

Curcumin Cancer Research by Type References

Colorectal Cancer (Cruz-Correa et al. 2006):
https://pubmed.ncbi.nlm.nih.gov/16757216/pubmed.ncbi.nlm.nih

Colorectal Cancer (He et al. 2011 – Phase IIa curcumin in advanced CRC; Anticancer Research):
https://pmc.ncbi.nlm.nih.gov/articles/PMC9072734/

Pancreatic Cancer (Dhillon et al. 2008 – Phase II; Clin Cancer Res):
https://pubmed.ncbi.nlm.nih.gov/18628464/pubmed.ncbi.nlm.nih

Breast Cancer (Hu et al. 2015 – curcumin sensitisessensitizes breast cancer cells; Molecular Cancer):
https://pubmed.ncbi.nlm.nih.gov/24318305/

Breast Cancer (Bayet-Robert et al. 2010 – dose-escalation with docetaxel):
https://pubmed.ncbi.nlm.nih.gov/19901561/pubmed.ncbi.nlm.nih

Prostate Cancer (Ide et al. 2012 – curcumin + soy isoflavones; Nutrition and Cancer/chemoprevention paper):
https://pubmed.ncbi.nlm.nih.gov/23136625/pubmed.ncbi.nlm.nih

Head & Neck Cancer (Rao et al. – turmeric/curcumin for radiation mucositis; Integr Cancer Ther):
https://pubmed.ncbi.nlm.nih.gov/24165896/pubmed.ncbi.nlm.nih

Multiple Myeloma (Golombick et al. 2009 – curcumin in MGUS/SMM and MM):
https://pubmed.ncbi.nlm.nih.gov/22473809/pubmed.ncbi.nlm.nih

Lung Cancer (Chen et al. 2014 – NSCLC, curcumin + cisplatin; PLoS One-type preclinical study):
https://pubmed.ncbi.nlm.nih.gov/24743574/ (representative Chen et al. NSCLC curcumin paper)onlinelibrary. wi

Gastric Cancer (Zhang et al. 2016 – curcumin and gastric cancer risk; Nutrients review/meta-style):

Curcumin's prevention of inflammation-driven early gastric cancer and its molecular mechanism https://pmc.ncl

Product Recommendations:

MCS formulas C3 liposomal curcumin contains 2.6 times more curcuminoids per capsule than the Doctor's Best and uses phospholipids from organic sunflower lecithin & chitosan, to promote the formation of neutrally charged liposomes. Read the **Comparing Curcumin Supplements** blog post here: https://myhealingcommunity.com/comparing-curcumin-supplements/

MCS Formulas
5% Discount Code:
Abbey5.

For cancer patients, the MCS Formulas Curcumin C3 Pro Liposomal (€38.62) offers superior bioavailability strength and purity compared to standard formulations, addressing curcumin's primary limitation.

Curcumin C3 Pro Liposomal: 60 caps, €38.62 https://www.mcsformulas.com/vitamins-supplements/curcumin-c3-liposomal/ref/14

MCS Formulas
5% Discount Code:
Abbey5.

For those on a budget or unable to take liposomal products, the standard Curcumin C3 (€52.95), combined with a Long Pepper/Piperine supplement, can achieve adequate absorption.

Curcumin C3 by MCS Formulas https://www.mcsformulas.com/vitamins-supplements/curcumin-c3-liposomal/ref/14

To get **5% off** MCS Formulas and support these free esearch summaries use
5% Discount Code: Abbey5.

Curcumin and Blood Cancers Research Support

Curcumin has some encouraging but still early evidence in several blood cancers, especially myeloma and early-stage CLL.

Curcumin in treatment of hematological cancers: Promises and challenges - ScienceDirect

Key research papers

Blood Cancer Type	Molecular Targets/ Mechanisms	Dose	Study Type	Research Title & Link
Multiple Myeloma	NF-κB, VEGF, TNF-α, IL-6	8 g/day oral curcumin (28 days)	Randomized clinical trial (n=33)	https://pmc.ncbi.nlm.nih.gov/articles/PMC9301229/
Multiple Myeloma	NF-κB (reduction)	4 g/day + 5 mg piperine BID	Clinical trial protocol	https://clinicaltrials.gov/study/NCT00113841
MGUS/ Smoldering Myeloma	Free light chain ratio, paraprotein	Oral curcumin with bioperine (variable doses)	Long-term follow-up study	https://www.oatext.com/Long-term-follow-up-of-curcumin-treated-MGUS-SMM-patientsan-updated-single-centre-experience.php
Pre-B Acute Lymphoblastic Leukemia	Caspase-3, AIF, PARP-1 (↑), Bcl-2 (↓)	In vitro dose-dependent (sub-IC50 with doxorubicin)	Pre-clinical (cell lines)	https://pubmed.ncbi.nlm.nih.gov/27644631/
Chronic Lymphocytic Leukemia (CLL)	Gli-1, Notch-1, Cyclin D1, lncRNA HOTAIR	Not specified (Phase II)	Phase II clinical trial	https://www.sciencedirect.com/science/article/pii/S0006497119379248
Chronic Lymphocytic Leukemia (CLL)	General anti-inflammatory & apoptotic pathways	4 g/day typical in trials	Clinical trial protocol	https://clinicaltrials.gov/study/NCT04731844
Leukemia (general)	PARP-1/ caspase-3, doxorubicin synergy	Preclinical models	Pre-clinical review	(2024 review) https://pmc.ncbi.nlm.nih.gov/articles/PMC10927384/
Lymphoma	NF-κB suppression	Preclinical (in vivo mouse models)	Pre-clinical (animal)	https://pmc.ncbi.nlm.nih.gov/articles/PMC10927384/
Hematologic Malignancies (general)	NF-κB, JAK/STAT, MAPK, Wnt/β-catenin	4–8 g/day typical range	Review/meta-analysis	https://www.sciencedirect.com/science/article/pii/S2225411023001116

A 2024 review on curcumin in hematological cancers concludes it can reduce viability and survival of leukemia, myeloma and lymphoma cells in preclinical models and promote apoptosis and cell-cycle arrest, mainly via NF-κB, JAK/STAT and related pathways.

Curcumin in treatment of hematological cancers: Promises and challenges - PMC

In vitro and animal work is substantial: curcumin induces apoptosis and chemosensitisation in leukemia cell lines (e.g., enhanced doxorubicin-induced death via PARP-1/caspase-3 pathways).

Curcumin Induces Apoptosis in Pre-B Acute Lymphoblastic Leukemia Cell Lines Via PARP-1 Cleavage - PubMed

Human data are limited and mostly small phase I/II trials, pilot studies and case reports; they suggest biological activity and safety, but not definitive survival benefit.

Curcumin as adjuvant therapy to improve remission in myeloma patients: A pilot randomized clinical trial - PMC

Current expert summaries (e.g., NCI PDQ) explicitly classify curcumin as a complementary agent under investigation rather than an established treatment.

Curcumin and Cancer (PDQ®) - NCI

Evidence by blood cancer type

Multiple myeloma and MGUS/SMM

A randomized single-blind trial (Indonesia, 33 myeloma patients) added **8 g/day oral curcumin** to melphalan–prednisone for 28 days and reported higher overall remission (75% vs 33.3%) plus bigger reductions in NF-κB, VEGF, TNF-α and IL-6 in the curcumin group.

Curcumin as adjuvant therapy to improve remission in myeloma patients: A pilot randomized clinical trial - PMC

Long-term single-centre work in MGUS/smouldering myeloma (MGUS/SMM) using oral curcumin (with bioperine in some protocols) has shown improvement in free light chain ratio and paraprotein trends in subsets of patients, although numbers are small and designs are not all randomized.

Long-term follow-up of curcumin treated MGUS/SMM patients – an updated single centre experience

A BMJ Case Reports paper described long-term disease stabilisation in a treatment-resistant myeloma patient on daily curcumin after standard options were exhausted; this is hypothesis-generating only.

Long-term stabilisation of myeloma with curcumin | BMJ Case Reports

ClinicalTrials.gov lists trials of curcumin ± piperine in MGUS/low-risk SMM and other settings, typically around **4 g/day curcumin with 5 mg** piperine twice daily, mainly to see if it delays progression and to track biomarkers.

Study Details | NCT00113841 | Curcumin (Diferuloylmethane Derivative) With or Without Bioperine in Patients With Multiple Myeloma | ClinicalTrials.gov

Leukemias

In pre-B acute lymphoblastic leukemia cell lines, curcumin causes dose-dependent loss of viability via apoptosis, increasing caspase-3, AIF, cleaved PARP-1 and decreasing Bcl-2; at sub-IC50 doses it significantly augments doxorubicin-induced cell death.

Curcumin in treatment of hematological cancers: Promises and challenges - PMC

A phase II study in previously untreated early-stage CLL combined curcumin with high-dose vitamin D; the regimen was reported as safe and well-tolerated, but the trial did not establish curcumin as a disease-modifying standard.

A Phase II Study of Curcumin and Vitamin D in Previously Untreated Patients with Early Stage Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) - ScienceDirect

Reviews describe curcumin reducing leukemia stem-cell markers (e.g., Gli-1, Notch-1, Cyclin D1), affecting drug resistance pathways such as lncRNA HOTAIR, and potentially improving chemosensitivity.

Curcumin in treatment of hematological cancers: Promises and challenges - PMC

Lymphomas and other hematologic malignancies

In lymphoma-bearing mice, curcumin suppressed NF-κB signalling and inhibited tumour growth in vivo.

Curcumin in treatment of hematological cancers: Promises and challenges - PMC

The broader 2025 and 2024 reviews of curcumin in cancer outline its modulation of NF-κB, MAPK, JAK/STAT and Wnt/β-catenin pathways that are relevant across many hematologic malignancies, but human lymphoma-specific trials are very limited.

Revisiting Curcumin in Cancer Therapy: Recent Insights into Molecular Mechanisms, Nanoformulations, and Synergistic Combinations - PMC

Curcumin form and dosing in the blood cancer literature

Dose range: Human blood-cancer trials typically use high-dose oral curcumin, often **4–8 g/day of standard curcumin w piperine,** sometimes divided doses.

Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer | Clinical Research Trial Listing

Bioavailability enhancers: Several protocols add piperine (Bioperine) to increase systemic levels (e.g., **4 g curcumin + 5 mg piperine twice daily** in MGUS/low-risk SMM study designs).

Study Details | NCT00113841 | Curcumin (Diferuloylmethane Derivative) With or Without Bioperine in Patients With Multiple Myeloma | ClinicalTrials.gov

Formulations: Most hematology studies used **oral capsules or tablets of curcumin** (sometimes branded standardized extracts), not the newer micellar/liposomal/nanoparticle forms, so we actually have more clinical data in the older, less bioavailable products.

A Phase II Study of Curcumin and Vitamin D in Previously Untreated Patients with Early Stage Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) - ScienceDirect

Safety: Across early-stage CLL and myeloma/MGUS/SMM studies, high-dose curcumin (with or without vitamin D or piperine) has generally been well tolerated, with GI upset being the main adverse event.

Long-term follow-up of curcumin treated MGUS/SMM patients – an updated single centre experience

When considering optional piperine or other bioavailability technology as in Liposomal, balance chocies against drug-interaction risk. e.g **piperine can affect CYP and drug levels.**

Revisiting Curcumin in Cancer Therapy: Recent Insights into Molecular Mechanisms, Nanoformulations, and Synergistic Combinations - PMC

Practical and safety considerations for taking curcumin when treating blood cancers

Curcumin can interact with chemotherapy and targeted agents via CYP enzymes and P-glycoprotein; some reviews highlight its potential to both overcome chemoresistance and, conversely, alter drug pharmacokinetics, so oncologist/pharmacist input is important.

Targeted therapies of curcumin focus on its therapeutic benefits in cancers and human health: Molecular signaling pathway-based approaches and future perspectives - ScienceDirect

It has antiplatelet effects and may theoretically increase bleeding risk when combined with anticoagulants or thrombocytopenia, which is relevant in leukemias and myeloma.

Curcumin and Cancer (PDQ®) - NCI

NCI notes that despite promising mechanisms and early clinical signals, curcumin should be viewed as an adjunct to, not a replacement for, evidence-based treatment; patients in trials remained under oncologic care.

Curcumin as adjuvant therapy to improve remission in myeloma patients: A pilot randomized clinical trial - PMC